Protagonist Therapeutics (PTGX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Clinical development and pipeline updates

• Multiple phase III studies are ongoing for the oral IL-23 antagonist, targeting psoriasis and ulcerative colitis, with key data expected by year-end and early next year.

• The ICONIC-LEAD and ICONIC-TOTAL studies are pivotal for regulatory filings and label expansion, including head-to-head superiority trials against leading competitors.

• A phase II ulcerative colitis study serves as a proof-of-principle, with potential expansion into Crohn's disease and psoriatic arthritis based on positive results.

• The rusfertide program for polycythemia vera completed phase III enrollment, with results anticipated in the first quarter of next year.

• Early-stage programs include oral IL-17 antagonists and obesity treatments, leveraging peptide technology for improved potency and specificity.

Strategic partnerships and financial outlook

• The J&J partnership has yielded over $170 million to date, with up to $700 million in milestones and 6–10% royalties on future sales.

• Near-term milestones include $215 million over the next 2–2.5 years, triggered by clinical and regulatory achievements.

• The Takeda partnership for rusfertide features a co-development, co-commercialization structure with a $300 million upfront payment and future opt-in/opt-out flexibility.

• Market opportunities for lead assets are substantial, with potential annual sales in the $5–14 billion range for IL-23 antagonists.

• The platform's versatility supports expansion into additional disease areas and targets, aiming for timely entry and differentiation.

Competitive positioning and innovation

• Oral peptide therapeutics are positioned as superior to small molecules in potency, specificity, and safety, especially in IL-17 and obesity indications.

• Head-to-head studies against established biologics demonstrate confidence in clinical efficacy and market potential.

• The obesity program targets a vast patient population, with peptide-based approaches enabling multi-agonist strategies not yet achieved by small molecules.

• The company maintains a significant lead in hepcidin mimetic development for PV, with second-generation oral candidates in the pipeline.

• Strategic selection of targets and rapid development are emphasized to maximize competitive advantage and market impact.